Lorena Lupinacci

3.9k total citations
17 papers, 121 citations indexed

About

Lorena Lupinacci is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Lorena Lupinacci has authored 17 papers receiving a total of 121 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 2 papers in Surgery. Recurrent topics in Lorena Lupinacci's work include Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (8 papers). Lorena Lupinacci is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Lung Cancer Treatments and Mutations (9 papers) and Lung Cancer Research Studies (8 papers). Lorena Lupinacci collaborates with scholars based in Argentina, United States and Spain. Lorena Lupinacci's co-authors include Aurelia Alexandru, Hossein Borghaei, A. Vergnenègre, Reyes Bernabé, Luis Paz‐Ares, Randeep Sangha, Martin Reck, Mariano Provencio, Julie R. Brahmer and Kenneth J. O’Byrne and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Lorena Lupinacci

14 papers receiving 120 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lorena Lupinacci Argentina 6 91 88 22 19 13 17 121
Aurelia Alexandru Romania 8 111 1.2× 111 1.3× 14 0.6× 24 1.3× 12 0.9× 24 155
Konstantin Penkov United States 5 116 1.3× 116 1.3× 20 0.9× 15 0.8× 10 0.8× 5 137
Giada Targato Italy 4 79 0.9× 61 0.7× 36 1.6× 29 1.5× 8 0.6× 18 119
Dimitris Mavroudis Greece 7 115 1.3× 35 0.4× 23 1.0× 43 2.3× 18 1.4× 7 153
Diego Kaen Argentina 4 87 1.0× 44 0.5× 24 1.1× 27 1.4× 23 1.8× 12 115
Joana L. Mora United States 2 47 0.5× 36 0.4× 47 2.1× 12 0.6× 11 0.8× 3 95
Jesus Corral Jaime Spain 6 124 1.4× 97 1.1× 46 2.1× 18 0.9× 12 0.9× 9 152
N. Girard France 4 81 0.9× 73 0.8× 10 0.5× 15 0.8× 19 1.5× 24 110
Emanuela Pozzi Switzerland 3 37 0.4× 48 0.5× 22 1.0× 26 1.4× 7 0.5× 5 90
J. Letreut France 5 120 1.3× 134 1.5× 34 1.5× 26 1.4× 4 0.3× 7 164

Countries citing papers authored by Lorena Lupinacci

Since Specialization
Citations

This map shows the geographic impact of Lorena Lupinacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lorena Lupinacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lorena Lupinacci more than expected).

Fields of papers citing papers by Lorena Lupinacci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lorena Lupinacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lorena Lupinacci. The network helps show where Lorena Lupinacci may publish in the future.

Co-authorship network of co-authors of Lorena Lupinacci

This figure shows the co-authorship network connecting the top 25 collaborators of Lorena Lupinacci. A scholar is included among the top collaborators of Lorena Lupinacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lorena Lupinacci. Lorena Lupinacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations
2.
Auclin, Édouard, Constance Thibault, Lorena Lupinacci, et al.. (2024). Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials. Lung Cancer. 199. 108039–108039. 1 indexed citations
3.
Oudard, Stéphane, Laura K. Aguilar, Lorena Lupinacci, et al.. (2023). OA15.05 Lung Immune Prognostic Index Predicts Outcomes from Upfront Chemotherapy + Immunotherapy +/- Antiangiogenic in Advanced NSCLC. Journal of Thoracic Oncology. 18(11). S80–S80. 1 indexed citations
4.
Brahmer, Julie R., Jong-Seok Lee, Tudor–Eliade Ciuleanu, et al.. (2022). Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.. Journal of Clinical Oncology. 40(17_suppl). LBA9025–LBA9025. 10 indexed citations
5.
Rizzo, Manglio, et al.. (2021). Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. International Journal of Clinical Oncology. 26(6). 1057–1064. 2 indexed citations
6.
Kaen, Diego, Lorena Lupinacci, Manglio Rizzo, et al.. (2021). P84.22 Outcomes of TKI Treatment in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Real-World Study in Argentina. Journal of Thoracic Oncology. 16(3). S667–S668. 1 indexed citations
7.
Denninghoff, Valeria, et al.. (2021). P86.18 Prevalence, Clinical Characteristics and Survival of Patients with KRAS Mutant Lung Cancer in Argentina.. Journal of Thoracic Oncology. 16(3). S680–S680. 4 indexed citations
8.
Rizzo, Manglio, et al.. (2021). P01.11 Clinical Outcomes After Discontinuation of Immunotherapy in Patients With Non-Progressing Metastatic Lung Cancer. Journal of Thoracic Oncology. 16(3). S240–S241. 1 indexed citations
9.
Borghaei, Hossein, Adam Płużański, Reyes Bernabé, et al.. (2020). Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227. Cancer Research. 80(16_Supplement). CT221–CT221. 22 indexed citations
10.
11.
Rízzí, María, et al.. (2019). P1.04-82 Toxicity as a Clinical Marker for Efficacy of Immunotherapy in NSCLC: A Multicentric Experience from Argentina. Journal of Thoracic Oncology. 14(10). S474–S475. 1 indexed citations
12.
Rízzí, María, et al.. (2019). EP1.04-41 Efficacy of Immunotherapy in Elderly Patients with Non-Small Cell Lung Cancer: A Multicentric Experience from Argentina. Journal of Thoracic Oncology. 14(10). S984–S984.
13.
14.
Martín, Claudio, Andrés F. Cardona, Zyanya Lucía Zatarain-Barrón, et al.. (2018). Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices. Oncology. 94(5). 297–305. 7 indexed citations
15.
Lupinacci, Lorena, et al.. (2017). P2.03-039 Compassionate Use of Osimertinib: Argentine Experience. Journal of Thoracic Oncology. 12(11). S2142–S2142.
16.
Lastiri, José, et al.. (2012). Age as a prognostic factor in osteosarcoma: Survival analysis.. Journal of Clinical Oncology. 30(15_suppl). 10074–10074. 1 indexed citations
17.
Biondo, Andrea, Tami Yap, Long Yan, et al.. (2011). Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3037–3037. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurelia Alexandru Breakdown of academic impact, for papers by Konstantin Penkov Breakdown of academic impact, for papers by Giada Targato Breakdown of academic impact, for papers by Dimitris Mavroudis Breakdown of academic impact, for papers by Diego Kaen Breakdown of academic impact, for papers by Joana L. Mora Breakdown of academic impact, for papers by Jesus Corral Jaime Breakdown of academic impact, for papers by N. Girard Breakdown of academic impact, for papers by Emanuela Pozzi Breakdown of academic impact, for papers by J. Letreut
Rankless by CCL
2026